Full federal rescheduling of psilocybin/MDMA out of Schedule I will not occur in 2026.

Predicted 2026-07-03 · Resolves 2026-12-31 · legislation · USA

90%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

In the US, psilocybin and MDMA sit in Schedule I — the government's most restrictive drug category, reserved for substances it says have no accepted medical use and high abuse potential. Moving a drug out of that category requires a lengthy scientific review by two federal agencies. That process hasn't even started for these drugs, so it can't finish by the end of 2026.

Resolution rule: YES if, as of 2026-12-31, no final rule has been published on federalregister.gov transferring psilocybin or MDMA out of Schedule I of the Controlled Substances Act. Check the DEA rules index at federalregister.gov/agencies/drug-enforcement-administration on 2026-12-31. If no such final rule exists, prediction (no rescheduling) resolves YES.

Schedule I controls hold. No enforcement infrastructure exists for legal supply chains, and diversion evidence keeps accumulating. Rescheduling requires an HHS/DEA scientific review process that has not been initiated for these substances, making a completed rescheduling in the calendar year effectively impossible.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →